March 22, 2023
BioSpace
InflaRx Reports Full Year 2022 Financial and Operating Results
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory ... See more »
XBiotech: XBiotech Inc.: FDA Approves XBiotech's IND in Rheumatology
Launching Novel True Human Antibody Therapy Natrunix to Treat RheumatologyAUSTIN, Texas, Dec. 13, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today reports that the FDA's Division of Rheu...
Read full article »
March 22, 2023
MarketScreener
Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate Update
(marketscreener.com) Fourth Quarter 2022 Net Revenue Increased 33% from Third Quarter 2022 While GAAP... See more »
March 21, 2023
BioSpace
XOMA Declares Quarterly Preferred Stock Dividends - March 21, 2023
XOMA Corporation (Nasdaq: XOMA) ("XOMA" or the "Company") today announced its Board of Directors has ... See more »
March 22, 2023Endpoints News
Novartis touts seven years of durability data for Zolgensma
The same day that Roche touted positive durability and safety data for its spinal muscular atrophy dr... See more »
March 23, 2023Medthority
FDA approves first-in-class Evkeeza for young children with homozygous familial hypercholesterolemia
Regeneron Pharmaceuticals, Inc. announced the FDA has extended the approval of Evkeeza (evinacumab-dg... See more »
March 23, 2023Owler
Agile Therapeutics's revenue changed from $8.40M in Sep 2022 to $10.88M in Dec 2022
Agile Therapeutics’s Trailing Twelve Months revenue changed from $8.40M in Sep 2022 to $10.88M in Dec... See more »
March 22, 2023FinSMEs
Flare Therapeutics Raises $123M in Series B Financing
Flare Therapeutics, a Cambridge, MA-based biotechnology company targeting transcription factors, rais... See more »
March 22, 2023Endpoints News
Regeneron scores label expansion for cholesterol drug Evkeeza
Regeneron's drug for a rare disease that causes high cholesterol has been expanded to include childre... See more »
March 22, 2023
BioSpace
InflaRx Reports Full Year 2022 Financial and Operating Results
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory ... See more »
March 22, 2023
MarketScreener
Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate Update
(marketscreener.com) Fourth Quarter 2022 Net Revenue Increased 33% from Third Quarter 2022 While GAAP... See more »
March 21, 2023
BioSpace
XOMA Declares Quarterly Preferred Stock Dividends - March 21, 2023
XOMA Corporation (Nasdaq: XOMA) ("XOMA" or the "Company") today announced its Board of Directors has ... See more »
March 22, 2023Endpoints News
Novartis touts seven years of durability data for Zolgensma
The same day that Roche touted positive durability and safety data for its spinal muscular atrophy dr... See more »
March 23, 2023Medthority
FDA approves first-in-class Evkeeza for young children with homozygous familial hypercholesterolemia
Regeneron Pharmaceuticals, Inc. announced the FDA has extended the approval of Evkeeza (evinacumab-dg... See more »
March 23, 2023Owler
Agile Therapeutics's revenue changed from $8.40M in Sep 2022 to $10.88M in Dec 2022
Agile Therapeutics’s Trailing Twelve Months revenue changed from $8.40M in Sep 2022 to $10.88M in Dec... See more »
March 22, 2023FinSMEs
Flare Therapeutics Raises $123M in Series B Financing
Flare Therapeutics, a Cambridge, MA-based biotechnology company targeting transcription factors, rais... See more »
March 22, 2023Endpoints News
Regeneron scores label expansion for cholesterol drug Evkeeza
Regeneron's drug for a rare disease that causes high cholesterol has been expanded to include childre... See more »
XBiotech is a biopharmaceutical company that develops antibody therapies for inflammatory diseases and colorectal cancer.
Read more